We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs, Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Multiple UDI Issuers Could Slow Adoption, Experts Tell FDA

Multiple UDI Issuers Could Slow Adoption, Experts Tell FDA

December 26, 2014

An FDA decision to allow multiple entities to issue unique device identifiers could backfire and actually impede the uptake of UDI, medical device and healthcare industry experts warn.

Speaking at a workshop hosted by the FDA, HHS’ Office of the National Coordinator for Health IT and Pew Charitable Trusts, panelists said having three different standards for UDI design is proving a significant barrier to the program’s launch.

“There’s no good case for the lack of a mandate” on a single UDI standard, said Leslie Kelly Hall, senior vice president at Healthwise and a member of the federal advisory committee on health IT. Other panelists agreed that UDI will only have value if it is widely adopted in a universal format.

Currently, devicemakers can obtain UDIs from one of three standards-issuing organizations: GS1, the Health Industry Business Communications Council or the International Council for Commonality in Blood Banking Automation. The idea, explained former FDA staffer and UDI architect Jay Crowley, was to minimize disruption of devicemaker operations. Many companies already work with GS1 and HIBCC, while ICCBA standards have wide currency in the blood and tissue markets, said Crowley, who is now a vice president at west coast consultancy USDM Life Sciences.

Russell Branzell, president and CEO of the College of Healthcare Information Management Executives, cautioned that allowing each hospital or healthcare system to implement UDI on its own could lead to “a big mess” where trading partners aren’t able to integrate their UDI systems. A clear, common UDI standard, along the lines of the drug code, is what is needed, he said.

Leigh Anderson, COO of informatics and technology services at Premier healthcare alliance in Charlotte, N.C., said integrating UDI into EHRs will require greater trust and collaboration throughout the industry. But, he added, the technology for sharing UDI data from a manufacturer’s system to a hospital’s system and then to a patient registry exists if stakeholders are willing to pool data. The problem is an abundance of proprietary technology that is blocking the way.

Some panelists suggested that the government could speed integration by insisting that EHRs accept UDI information to gain government certification. “We need to educate software vendors on UDI,” said Joseph Drozda, director of outcomes research at Sisters of Mercy Health System in St. Louis, Mo. “It doesn’t seem like it should be a big deal for any one vendor; they have to know how much customers want this.”

Another sticky wicket is that hospitals still need to find some efficient way to get UDIs into EHRs, as time is at a premium. “For patient safety, the last thing we want is manual UDI entry into the clinical record,” said Chantal Worzala, director of policy at the American Hospital Association. She pointed out that each UDI involves up to 75 characters, and many medical procedures use multiple device components.

The next time you hear about UDIs, it may be from an FDA investigator. Will you be ready with an answer? Stay up to date on all the latest UDI developments with How to Implement UDI: A Guide for Devicemakers.

Devices Inspections and Audits

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NVIDIA and Medtronic to Develop Artificial Intelligence Solutions

  • FDA Approves Evkeeza for Kids With Ultra-Rare Cholesterol Disorder

  • GrayMatters Health’s Digital Therapy Device for PTSD Cleared

  • Dupixent Shows Positive Results in COPD Study

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

Managing Effective CAPA Systems — Nine of the industry’s top experts, who have together managed thousands of root cause investigations and successfully opened and closed more CAPAs than they can remember, share everything from simple nuts and bolts to the most innovative best practices. Order today.